What is Rocket Pharmaceuticals, Inc. Warrant's earnings per share (EPS)?

Rocket Pharmaceuticals, Inc. Warrant (RCKTW) reported diluted earnings per share of -$2.01 for fiscal year 2025. This represents a 26.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Rocket Pharmaceuticals, Inc. Warrant (RCKTW) Financials

RCKTW

FY2025 annual

Revenue $0 YoY not available

Net Income -$223.1M +13.8% YoY

EPS (Diluted) -$2.01 +26.4% YoY

Free Cash Flow -$190.5M +11.7% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 10, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RCKTW SEC filings page.

Rocket Pharmaceuticals, Inc. Warrant (RCKTW) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RCKTW FY2025 2026-08-30

Development-stage economics remain defined by R&D spending, persistent cash consumption, and shrinking balance-sheet funding capacity.

Net loss narrowed to $223M in FY2025 while operating cash use was $190M. Because both measures improved from FY2024, the earnings change translated into less cash consumption rather than appearing only through accounting adjustments.

R&D spending fell from $171M in FY2024 to $142M in FY2025, making lower operating expense the clearest explanation for the reduced loss; the supplied data does not establish a change in unit economics.

Capital intensity is minimal: free cash flow nearly matched operating cash flow because capital expenditures were only $440K. Meanwhile, total assets fell from $528M to $330M, and financing cash flow dropped from $186M to $148K, indicating that reduced cash use came alongside a much smaller funding base.

Financial Health Signals

Financial health score not available

Rocket Pharmaceuticals, Inc. Warrant does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/7

Rocket Pharmaceuticals, Inc. Warrant passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Rocket Pharmaceuticals, Inc. Warrant reported a net loss of $223.1M while operations used $190.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Rocket Pharmaceuticals, Inc. Warrant reported an operating loss of $231.7M against $1.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

Rocket Pharmaceuticals, Inc. Warrant generated $0 in revenue in Q2 2026.

EBITDA

-$45.3M

YoY+34.5%

QoQ+3.4%

Rocket Pharmaceuticals, Inc. Warrant's EBITDA was -$45.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 34.5% from the same quarter a year earlier. Against the prior quarter it is up 3.4%.

Net Income

$123.2M

YoY+278.8%

QoQ+358.9%

Rocket Pharmaceuticals, Inc. Warrant reported $123.2M in net income in Q2 2026. This represents an increase of 278.8% from the same quarter a year earlier. Against the prior quarter it is up 358.9%.

EPS (Diluted)

$1.08

YoY+274.2%

QoQ+357.1%

Rocket Pharmaceuticals, Inc. Warrant earned $1.08 per diluted share (EPS) in Q2 2026. This represents an increase of 274.2% from the same quarter a year earlier. Against the prior quarter it is up 357.1%.

Cash & Balance Sheet

Free Cash Flow

-$39.6M

YoY+19.2%

QoQ+12.9%

Rocket Pharmaceuticals, Inc. Warrant recorded an outflow of $39.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 19.2% from the same quarter a year earlier. Against the prior quarter it is up 12.9%.

Cash & Debt

$224.5M

YoY+584.1%

QoQ+352.5%

5Y CAGR-3.2%

10Y CAGR+19.3%

Rocket Pharmaceuticals, Inc. Warrant held $224.5M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

110M

YoY+1.7%

QoQ+0.5%

5Y CAGR+11.5%

10Y CAGR+15.1%

Rocket Pharmaceuticals, Inc. Warrant had 110M shares outstanding in Q2 2026. This represents an increase of 1.7% from the same quarter a year earlier. Against the prior quarter it is up 0.5%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

33.4%

YoY+52.9pp

QoQ+53.4pp

Rocket Pharmaceuticals, Inc. Warrant's ROE was 33.4% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 52.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 53.4 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$29.5M

YoY-30.9%

QoQ-6.2%

Rocket Pharmaceuticals, Inc. Warrant invested $29.5M in research and development in Q2 2026. This represents a decrease of 30.9% from the same quarter a year earlier. Against the prior quarter it is down 6.2%.

Capital Expenditures

$8K

YoY-84.0%

QoQ-91.4%

5Y CAGR-64.6%

10Y CAGR-28.2%

Rocket Pharmaceuticals, Inc. Warrant invested $8K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 84.0% from the same quarter a year earlier. Against the prior quarter it is down 91.4%.

Share Buybacks

Not reported for Q2 2026.

RCKTW Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RCKTW quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Revenue	N/A	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A	N/A
R&D Expenses	N/A	$142.0M-17.1%	$171.2M-8.1%	$186.3M+12.5%	$165.6M+32.0%	$125.5M+19.0%	$105.4M+82.1%	$57.9M+8.7%	$53.3M+257.1%	$14.9M+148.9%	$6.0M-52.3%	$12.6M+124.5%	$5.6M
SG&A Expenses	N/A	$86.5M-15.2%	$102.0M+39.1%	$73.3M+24.7%	$58.8M+40.7%	$41.8M+44.7%	$28.9M+58.2%	$18.2M+2.0%	$17.9M+268.4%	$4.9M+207.3%	$1.6M-79.9%	$7.8M+271.3%	$2.1M
Operating Income	N/A	-$231.7M+15.2%	-$273.2M-5.2%	-$259.7M-15.7%	-$224.3M-34.1%	-$167.2M-24.5%	-$134.3M-76.4%	-$76.2M-7.0%	-$71.2M-259.9%	-$19.8M-161.1%	-$7.6M+62.9%	-$20.4M-164.7%	-$7.7M
EBITDA	N/A	-$222.8M+16.2%	-$266.0M-4.4%	-$254.8M-15.6%	-$220.4M-34.4%	-$164.0M-23.2%	-$133.2M-75.8%	-$75.7M-6.9%	-$70.8M-261.9%	-$19.6M-160.7%	-$7.5M+63.1%	-$20.4M-164.2%	-$7.7M
Interest Expense	N/A	$1.9M+0.3%	$1.9M+0.6%	$1.9M+0.7%	$1.9M-37.5%	$3.0M-57.3%	$7.0M+16.9%	$6.0M-1.3%	$6.0M	$0	$0-100.0%	$1.2M+25.5%	$980K
Income Tax	N/A	$0	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$223.1M+13.8%	-$258.7M-5.4%	-$245.6M-10.7%	-$221.9M-31.2%	-$169.1M-21.0%	-$139.7M-80.8%	-$77.3M-3.7%	-$74.5M-280.6%	-$19.6M-158.5%	-$7.6M+88.9%	-$68.0M-613.3%	-$9.5M
EPS (Basic)	N/A	-$2.01+26.4%	-$2.73+6.5%	-$2.92+10.4%	-$3.26-22.1%	-$2.67-6.0%	-$2.52-59.5%	-$1.58	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.17	-$2.01+26.4%	-$2.73+6.5%	-$2.92+10.4%	-$3.26-22.1%	-$2.67-6.0%	-$2.52-59.5%	-$1.58	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	111M+17.2%	95M+12.9%	84M+23.3%	68M+7.8%	63M+14.2%	55M+13.0%	49M	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$0	$0	N/A	$0	$0	$0	N/A	$0
R&D Expenses	$29.5M-30.9%	$31.5M-12.5%	N/A	$34.1M-19.5%	$42.7M-8.0%	$35.9M-20.5%	N/A	$42.3M-9.7%
SG&A Expenses	$17.4M-30.4%	$17.1M-40.0%	N/A	$18.4M-32.3%	$25.0M-8.6%	$28.4M+28.4%	N/A	$27.1M+45.9%
Operating Income	-$46.9M+34.1%	-$48.5M+24.7%	N/A	-$52.2M+24.7%	-$71.1M+3.5%	-$64.4M+4.4%	N/A	-$69.4M-6.1%
EBITDA	-$45.3M+34.5%	-$46.9M+24.2%	N/A	-$49.5M+26.6%	-$69.1M+3.8%	-$61.9M+5.8%	N/A	-$67.5M-5.1%
Interest Expense	$473K0.0%	$473K+0.2%	N/A	$473K+0.4%	$473K+0.4%	$472K+0.2%	N/A	$471K+0.4%
Income Tax	$8.6M	N/A	N/A	N/A	$0	N/A	N/A	N/A
Net Income	$123.2M+278.8%	-$47.6M+22.4%	N/A	-$50.3M+24.6%	-$68.9M+1.0%	-$61.3M+1.2%	N/A	-$66.7M-7.8%
EPS (Basic)	$1.09+275.8%	-$0.42+25.0%	-$0.38+38.7%	-$0.45+36.6%	-$0.62+16.2%	-$0.56+15.2%	-$0.620.0%	-$0.71+5.3%
EPS (Diluted)	$1.08+274.2%	-$0.42+25.0%	-$0.38+38.7%	-$0.45+36.6%	-$0.62+16.2%	-$0.56+15.2%	-$0.620.0%	-$0.71+5.3%
Diluted Shares (Avg)	115M+3.1%	112M+1.9%	N/A	112M+18.5%	111M+18.4%	110M+17.7%	N/A	94M+13.9%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

RCKTW Balance Sheet

RCKTW quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Total Assets	$330.4M-37.4%	$527.7M-6.8%	$566.3M+2.6%	$551.8M+11.0%	$497.0M-15.9%	$590.8M+58.8%	$372.1M+48.1%	$251.3M+1147.4%	$20.1M-84.5%	$129.6M+14.4%	$113.3M+1952.9%	$5.5M
Current Assets	$192.7M-49.0%	$378.2M0.0%	$378.2M+3.9%	$364.1M-7.1%	$392.1M-19.6%	$487.3M+58.4%	$307.8M+47.2%	$209.1M+1003.1%	$19.0M-85.2%	$128.3M+14.2%	$112.4M+2961.7%	$3.7M
Cash & Equivalents	$77.6M-52.6%	$163.6M+192.7%	$55.9M-60.2%	$140.5M-39.6%	$232.7M-21.7%	$297.1M+60.3%	$185.4M+66.5%	$111.4M+513.8%	$18.1M-39.1%	$29.8M-62.8%	$80.0M+2112.3%	$3.6M
Short-Term Investments	$111.4M-46.6%	$208.7M-34.2%	$317.3M+47.0%	$215.9M+38.3%	$156.0M-15.9%	$185.6M+56.3%	$118.7M+25.8%	$94.4M	$0-100.0%	$96.7M+209.5%	$31.2M	$0
Long-Term Investments	$0	$0-100.0%	$34.3M-20.7%	$43.3M	$0	$0	$0-100.0%	$7.4M	$0	$0	$0	$0
Goodwill	$39.2M0.0%	$39.2M0.0%	$39.2M-0.1%	$39.2M+27.2%	$30.8M0.0%	$30.8M0.0%	$30.8M0.0%	$30.8M	$0	N/A	N/A	N/A
Total Liabilities	$53.2M-17.4%	$64.5M-12.6%	$73.8M+18.7%	$62.1M+46.9%	$42.3M-51.6%	$87.3M+34.7%	$64.8M+13.2%	$57.3M+1137.6%	$4.6M-96.2%	$121.3M+24.0%	$97.8M+71.3%	$57.1M
Current Liabilities	$30.2M-25.8%	$40.7M-16.1%	$48.5M+23.8%	$39.2M+76.7%	$22.2M-32.0%	$32.6M+78.1%	$18.3M+19.1%	$15.4M+240.0%	$4.5M-35.8%	$7.0M+70.1%	$4.1M-42.7%	$7.2M
Non-Current Liabilities	$23.0M-3.2%	$23.8M-5.9%	$25.3M+10.1%	$23.0M+14.0%	$20.1M-63.2%	$54.7M+17.6%	$46.5M+11.0%	$41.9M+39062.6%	$107K-99.9%	$114.2M+22.0%	$93.6M+87.8%	$49.9M
Total Equity	$277.2M-40.2%	$463.2M-6.0%	$492.6M+0.6%	$489.7M+7.7%	$454.7M-9.7%	$503.5M+63.9%	$307.3M+58.4%	$194.0M+1150.3%	$15.5M+85.4%	$8.4M-46.1%	$15.5M+130.1%	-$51.6M
Retained Earnings	-$1.4B-18.3%	-$1.2B-27.0%	-$959.4M-34.4%	-$713.8M-45.1%	-$491.9M-52.4%	-$322.8M-76.3%	-$183.1M-73.0%	-$105.9M-237.7%	-$31.4M+86.9%	-$238.9M-21.9%	-$196.0M-53.1%	-$128.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$423.1M+0.5%	$285.4M-39.4%	$330.4M-37.4%	$368.0M-6.5%	$421.0M-5.7%	$471.1M-5.7%	$527.7M-6.8%	$393.7M-34.2%
Current Assets	$289.6M+4.5%	$149.8M-53.8%	$192.7M-49.0%	$227.7M-5.8%	$277.2M-5.3%	$324.5M-6.0%	$378.2M0.0%	$241.8M-45.9%
Cash & Equivalents	$224.5M+584.1%	$49.6M-0.4%	$77.6M-52.6%	$75.9M+15.8%	$32.8M-15.0%	$49.8M+41.2%	$163.6M+192.7%	$65.6M-70.9%
Short-Term Investments	$59.2M-75.2%	$94.8M-64.7%	$111.4M-46.6%	$146.8M-13.7%	$238.7M-0.6%	$268.4M-9.0%	$208.7M-34.2%	$170.1M-19.6%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0-100.0%	$0
Goodwill	$39.2M0.0%	$39.2M0.0%	$39.2M0.0%	$39.2M0.0%	$39.2M0.0%	$39.2M0.0%	$39.2M0.0%	$39.2M0.0%
Total Liabilities	$54.3M-18.7%	$47.4M-19.6%	$53.2M-17.4%	$54.4M-14.9%	$66.8M+8.1%	$58.9M+1.7%	$64.5M-12.6%	$63.9M+10.8%
Current Liabilities	$31.3M-27.8%	$24.5M-30.7%	$30.2M-25.8%	$31.2M-22.0%	$43.4M+15.4%	$35.3M+7.1%	$40.7M-16.1%	$40.0M+19.4%
Non-Current Liabilities	$22.9M-1.8%	$22.9M-3.0%	$23.0M-3.2%	$23.2M-3.1%	$23.4M-3.4%	$23.6M-5.5%	$23.8M-5.9%	$23.9M-1.1%
Total Equity	$368.8M+4.1%	$238.0M-42.2%	$277.2M-40.2%	$313.7M-4.9%	$354.2M-7.9%	$412.1M-6.7%	$463.2M-6.0%	$329.8M-39.1%
Retained Earnings	-$1.4B-1.3%	-$1.5B-16.4%	-$1.4B-18.3%	-$1.4B-20.8%	-$1.3B-23.6%	-$1.3B-25.3%	-$1.2B-27.0%	-$1.2B-28.7%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.

RCKTW Cash Flow Statement

RCKTW quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Operating Cash Flow	-$170.3M	-$190.0M+9.4%	-$209.7M-7.6%	-$194.9M-9.4%	-$178.1M-47.0%	-$121.2M-62.3%	-$74.6M-15.4%	-$64.7M-20.2%	-$53.8M-237.0%	-$16.0M-190.1%	-$5.5M+68.4%	-$17.4M-78.8%	-$9.7M
Depreciation & Amortization	N/A	$8.9M+23.6%	$7.2M+46.9%	$4.9M+25.6%	$3.9M+21.9%	$3.2M+179.5%	$1.1M+168.8%	$426K+29.1%	$330K+61.8%	$204K+204.5%	$67K+48.9%	$45K	$0
Stock-Based Compensation	N/A	$37.1M-15.6%	$43.9M+11.5%	$39.4M+27.1%	$31.0M+6.1%	$29.2M+57.5%	$18.6M+38.9%	$13.4M-1.7%	$13.6M+930.4%	$1.3M+381.8%	$274K-88.5%	$2.4M+1244.6%	$177K
Capital Expenditures	$127K	$440K-92.5%	$5.9M-64.3%	$16.4M+96.6%	$8.4M+9.7%	$7.6M-63.0%	$20.6M-11.4%	$23.3M+1501.4%	$1.5M+91.2%	$760K+126.9%	$335K-18.7%	$412K	N/A
Free Cash Flow	-$170.5M	-$190.5M+11.7%	-$215.6M-2.0%	-$211.4M-13.3%	-$186.5M-44.8%	-$128.8M-35.2%	-$95.2M-8.3%	-$87.9M-59.2%	-$55.2M-230.3%	-$16.7M-186.4%	-$5.8M+67.3%	-$17.8M	N/A
Investing Cash Flow	$361.8M	$103.8M-21.2%	$131.7M+234.3%	-$98.1M-41.5%	-$69.3M-467.7%	$18.9M+119.5%	-$96.6M-147.6%	-$39.0M-640.0%	-$5.3M-593.7%	-$760K-126.9%	-$335K	N/A	N/A
Financing Cash Flow	$82K	$148K-99.9%	$185.7M-10.9%	$208.4M+34.2%	$155.3M+312.1%	$37.7M-86.7%	$283.0M+59.2%	$177.8M+15.8%	$153.5M+504.2%	$25.4M+158687.5%	$16K	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$72K	$0	$0	$0	$0	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$39.6M+19.1%	-$45.4M+18.6%	-$34.8M+25.8%	-$50.4M+3.2%	-$49.0M+9.0%	-$55.8M+1.9%	-$46.9M-60.0%	-$52.1M+8.8%
Depreciation & Amortization	$1.6M-20.0%	$1.6M-36.0%	$1.7M-5.6%	$2.7M+42.1%	$2.0M+11.1%	$2.5M+47.1%	$1.8M+28.6%	$1.9M+58.3%
Stock-Based Compensation	$7.4M-31.7%	$8.5M-17.8%	N/A	$9.8M-13.2%	$10.9M-4.2%	$10.3M+0.8%	N/A	$11.2M+9.0%
Capital Expenditures	$8K-84.0%	$93K-74.5%	$80K-74.1%	-$54K-96.6%	$50K-97.4%	$364K-82.1%	$309K-93.4%	$1.6M-65.9%
Free Cash Flow	-$39.6M+19.2%	-$45.5M+19.0%	-$34.9M+26.1%	-$50.5M+6.0%	-$49.0M+12.1%	-$56.2M+4.6%	-$47.3M-39.0%	-$53.7M+13.1%
Investing Cash Flow	$214.4M+574.9%	$17.4M+130.1%	$36.4M+196.2%	$93.6M+18.6%	$31.8M-42.9%	-$58.0M-265.7%	-$37.9M+73.1%	$78.9M+63.5%
Financing Cash Flow	$150K-30.2%	-$1K	$0-100.0%	-$67K-138.1%	$215K-85.9%	$0-100.0%	$182.8M+46664.5%	$176K-99.9%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

RCKTW Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RCKTW quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Return on Equity	-80.5%-24.6pp	-55.9%-6.0pp	-49.9%-4.5pp	-45.3%-8.1pp	-37.2%-9.4pp	-27.7%-2.6pp	-25.1%+13.3pp	-38.4%+87.8pp	-126.2%-35.7pp	-90.5%+347.0pp	-437.5%	N/A
Return on Assets	-67.5%-18.5pp	-49.0%-5.7pp	-43.4%-3.2pp	-40.2%-6.2pp	-34.0%-10.4pp	-23.6%-2.9pp	-20.8%+8.9pp	-29.6%+67.5pp	-97.2%-91.3pp	-5.8%+54.1pp	-60.0%+112.7pp	-172.7%
Current Ratio	6.38-2.9x	9.30+1.5x	7.80-1.5x	9.29-8.4x	17.69+2.7x	14.94-1.9x	16.81+3.2x	13.60+9.4x	4.19-14.0x	18.23-8.9x	27.14+26.6x	0.51
Debt-to-Equity	0.19+0.1x	0.140.0x	0.150.0x	0.130.0x	0.09-0.1x	0.170.0x	0.21-0.1x	0.300.0x	0.30-14.2x	14.49+8.2x	6.29	N/A
Asset Turnover	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.00	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	33.4%+52.9pp	-20.0%-5.1pp	N/A	-16.1%+4.2pp	-19.5%-1.3pp	-14.9%-0.8pp	N/A	-20.2%-8.8pp
Return on Assets	29.1%+45.5pp	-16.7%-3.7pp	N/A	-13.7%+3.3pp	-16.4%-0.8pp	-13.0%-0.6pp	N/A	-17.0%-6.6pp
Current Ratio	9.24+2.9x	6.12-3.1x	6.38-2.9x	7.30+1.3x	6.39-1.4x	9.19-1.3x	9.30+1.5x	6.05-7.3x
Debt-to-Equity	0.150.0x	0.20+0.1x	0.19+0.1x	0.170.0x	0.190.0x	0.140.0x	0.140.0x	0.19+0.1x
Asset Turnover	0.000.0x	0.000.0x	N/A	0.000.0x	0.000.0x	0.000.0x	N/A	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Where Rocket Pharmaceuticals, Inc. Warrant Ranks

Frequently Asked Questions

What is Rocket Pharmaceuticals, Inc. Warrant's annual revenue?

Rocket Pharmaceuticals, Inc. Warrant (RCKTW) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Rocket Pharmaceuticals, Inc. Warrant profitable?

No, Rocket Pharmaceuticals, Inc. Warrant (RCKTW) reported a net income of -$223.1M in fiscal year 2025.

What is Rocket Pharmaceuticals, Inc. Warrant's EBITDA?

Rocket Pharmaceuticals, Inc. Warrant (RCKTW) had EBITDA of -$222.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Rocket Pharmaceuticals, Inc. Warrant's return on equity (ROE)?

Rocket Pharmaceuticals, Inc. Warrant (RCKTW) has a return on equity of -80.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Rocket Pharmaceuticals, Inc. Warrant's free cash flow?

Rocket Pharmaceuticals, Inc. Warrant (RCKTW) recorded an outflow of $190.5M in free cash flow during fiscal year 2025. This represents a 11.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Rocket Pharmaceuticals, Inc. Warrant's operating cash flow?

Rocket Pharmaceuticals, Inc. Warrant (RCKTW) recorded an outflow of $190.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Rocket Pharmaceuticals, Inc. Warrant's total assets?

Rocket Pharmaceuticals, Inc. Warrant (RCKTW) had $330.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Rocket Pharmaceuticals, Inc. Warrant's capital expenditures?

Rocket Pharmaceuticals, Inc. Warrant (RCKTW) invested $440K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Rocket Pharmaceuticals, Inc. Warrant spend on research and development?

Rocket Pharmaceuticals, Inc. Warrant (RCKTW) invested $142.0M in research and development during fiscal year 2025.

How many shares does Rocket Pharmaceuticals, Inc. Warrant have outstanding?

Rocket Pharmaceuticals, Inc. Warrant (RCKTW) had 109M shares outstanding as of fiscal year 2025.

What is Rocket Pharmaceuticals, Inc. Warrant's current ratio?

Rocket Pharmaceuticals, Inc. Warrant (RCKTW) had a current ratio of 6.38 as of fiscal year 2025, which is generally considered healthy.

What is Rocket Pharmaceuticals, Inc. Warrant's debt-to-equity ratio?

Rocket Pharmaceuticals, Inc. Warrant (RCKTW) had a debt-to-equity ratio of 0.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Rocket Pharmaceuticals, Inc. Warrant's return on assets (ROA)?

Rocket Pharmaceuticals, Inc. Warrant (RCKTW) had a return on assets of -67.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Rocket Pharmaceuticals, Inc. Warrant's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Rocket Pharmaceuticals, Inc. Warrant (RCKTW) held $188.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $190.0M over that year. Dividing the one by the other, the reported balance equals about 12 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Rocket Pharmaceuticals, Inc. Warrant's Piotroski F-Score?

Rocket Pharmaceuticals, Inc. Warrant (RCKTW) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Rocket Pharmaceuticals, Inc. Warrant's earnings high quality?

Rocket Pharmaceuticals, Inc. Warrant (RCKTW) reported a net loss of $223.1M while operations used $190.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Rocket Pharmaceuticals, Inc. Warrant cover its interest payments?

Rocket Pharmaceuticals, Inc. Warrant (RCKTW) reported an operating loss of $231.7M against $1.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.